AbbVie (ABBV)

AbbVie's price is sitting about a fifth above where it was trading half a year ago.

What is going on right now?

The stock has climbed steadily and recently moved well past its longer-term price trends. That climb has been unusually fast, and streaks like this have often paused before continuing in either direction.

How is the business itself doing?

AbbVie makes medicines like Skyrizi, Rinvoq, and Botox. Sales grew about 10% recently, and reported profits jumped sharply. The company brings in roughly $17 billion a year in cash, though it currently pays out more in dividends than it earns in profit.

What stands out?

Its short-term bills actually exceed its short-term cash and assets, 81 cents on hand for every dollar owed soon. That is unusual for a company this large.

What comes next?

Reports suggest oil above $116 could push up costs for the whole healthcare supply chain, and AbbVie's next earnings will show whether that pressure reaches its margins.